Lisa A Carey MD
Professor of Hematology & Oncology, University of North Carolina School of Medicine
Join to View Full Profile
101 Manning DrChapel Hill, NC 27514
Phone+1 919-966-4996
Fax+1 919-843-5515
Dr. Carey is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1993 - 1997- Johns Hopkins UniversityResidency, Internal Medicine, 1990 - 1993
- Johns Hopkins University School of MedicineClass of 1990
Certifications & Licensure
NC State Medical License 1997 - 2026
MD State Medical License 1993 - 1998
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
Clinical Trials
- Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer Start of enrollment: 1998 Dec 01
- Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer Start of enrollment: 2005 Nov 01
- Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen Start of enrollment: 2008 Jun 18
Publications & Presentations
PubMed
- Prognostic value of visually and computationally-assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030).Guilherme Nader-Marta, Xiangying Chu, Satabhisa Mukhopadhyay, Vandana G Abramson, Adam Brufsky
Journal of the National Cancer Institute. 2025-10-11 - The MEK inhibitor trametinib incurs mitochondrial injury and induces innate immune responses in the mouse heart.Kelsey H Fisher-Wellman, Richard D Lutze, Logan G Kirkland, Ju Youn Beak, Samantha M Morrissey
Biorxiv. 2025-09-08 - Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer.Frederick M Howard, James Dolezal, Hanna Hieromnimon, Sara Venters, Sara Kochanny
Medrxiv. 2025-08-27
Journal Articles
- Integrated Analysis of RNA and DNA from a Phase III Trial of Trastuzumab-Based Neoadjuvant Chemotherapy Identifies Response Predictors in HER2-Positive Breast CancerLisa Carey, MD, Clinical Cancer Research
Authored Content
- Key Immunotherapy Presentations in Early Breast Cancer from ESMO 2023: KEYNOTE-756, CheckMate-7FL, and Updated KEYNOTE-522October 2023
- Endocrine-Based Therapy for Early and Metastatic Breast Cancer: New Horizons from ASCO 2023June 2023
Press Mentions
Newsworthy from the School of Medicine, Week of September 19 – September 25September 24th, 2025- Everolimus plus Carboplatin Shows Promise in TNBCSeptember 1st, 2025
- UNC Cancer Center Awarded $28M to Lead ‘Adaptive’ Clinical TrialAugust 11th, 2025
Grant Support
- Elucidating the molecular mechanisms of metastasis organ tropismUNIV OF NORTH CAROLINA CHAPEL HILL2025–2030
- Optimizing prognostic and predictive algorithms using residual disease (RD) genomic biomarkers in HER2+ and TNBCUNIV OF NORTH CAROLINA CHAPEL HILL2019–2030
- SPORE in Breast CancerUNIV OF NORTH CAROLINA CHAPEL HILL1997–2029
- UNC Lead Academic Participating SiteUNIV OF NORTH CAROLINA CHAPEL HILL2019–2025
- Breast Cancer ResearchNational Cancer Institute2011–2012
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
